Posted by Michael Wonder on 08 May 2025
FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
8 May 2025 - Today, the FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem) for adults with KRAS mutated recurrent low grade serous ovarian cancer who have received prior systemic therapy.
Efficacy was evaluated in RAMP-201, an open-label, multi-centre trial that included 57 adults with measurable KRAS mutated recurrent low grade serous ovarian cancer.
